Quantigen is latest in series of life science firms growing in city
Quantigen Biosciences, a specialty contract research organization focused on medical diagnostics and device development through pharmaceutical and biotech industry partnerships, has announced its plans to relocate and expand its headquarters from its existing location to a 40,000 square-foot state-of-the-art facility located at the Round Room building in Fishers, 10300 Kincaid Drive.
Accompanying this announcement, the firm plans to add 30 new, high-wage jobs in the areas of quality and regulatory compliance and research by the end of 2023 and will invest $2.5 million into new lab and office space.
Elliott
“The Fishers community has been home to Quantigen since our founding, so we are thrilled to have been able to find a facility that can support our expansion and allow us to continue operations in the city where we have been welcomed and supported,” Quantigen CEO Jami Elliott said. “Mayor Fadness and his team have been incredibly supportive throughout our relocation search process. We are bullish for Quantigen’s future, as we are for the biotech prospects for our city and the region as a whole.”
Quantigen plans to double its workforce, a result of efforts in three strategic areas:
- Increased demand from pharma and biotech companies to develop new diagnostic tests and platform technologies.
- Support for grant sponsored research through the Bill & Melinda Gates Foundation in the areas of high throughput test development for soil transmitted helminths, COVID-19 and tuberculosis.
- A recent U.S. Centers for Medicare and Medicaid Services MolDx coverage decision award for a novel genetic test that is used to aid health care providers in medication selection and to improve medication safety.
Fadness
“Jami and his team at Quantigen are working on next-generation technology for the life science industry right here in Fishers,” Fishers Mayor Scott Fadness said. “Quantigen’s commitment to staying and investing in this community is exciting as we continue to see catalytic growth in this cluster that’s ripe for Fishers.”
The Indiana Economic Development Corporation offered Quantigen LLC up to $350,000 in conditional tax credits based on the company’s plans to create up to 23 new jobs by the end of 2023. These tax credits are performance-based, meaning the company is eligible to claim incentives once Hoosiers are hired.
Staton
“We’re thrilled to support Quantigen’s growing presence in Indiana as they continue strengthening our state’s life sciences sector, which contributes roughly $80 billion to Indiana’s economy,” Interim Indiana Secretary of Commerce Jim Staton said. “I’m confident Quantigen’s success will continue for years to come and grateful for the high-quality career opportunities they’re providing for Hoosiers.”
This comes on the heels of recent life science firms announcing their growth and investment in the city, including Stevanato, a foreign-direct investment equating to $145 million and 230 jobs; INCOG BioPharma, investing $60 million and 150 jobs; and Genezen, investing $7.8 million and 36 employees.
The City of Fishers provided Quantigen with a $50,000 grant toward its buildout and moving expenses. The Redevelopment Commission approved the Economic Development Agreement at the Feb. 2 meeting with the abatement approval being presented to City Council at the July meeting.
For more information about Quantigen or to learn about job opportunities, visit quantigen.com.